Repurposing Existing Drugs for COVID-19: An Endocrinology Perspective

September 2020 in “ BMC Endocrine Disorders ”

Flavio A. Cadegiani

dexamethasone glucocorticoid anti-androgens statins ACE inhibitors renin-angiotensin-aldosterone system RAAS angiotensin-converting enzyme-2 ACE2 TMPRSS2 corticosteroid blood pressure medications cholesterol-lowering drugs

Studysummary This review highlights that while dexamethasone may reduce mortality in severe COVID-19, no other drugs have proven effectiveness for treatment, emphasizing the need for clinical trials of existing medications.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on bmcendocrdisord.biomedcentral.com →

Discuss this study in the Community →

Research cited in this study

8 / 8 results

research Anti-Androgens May Protect Against Severe COVID-19 Outcomes: Results From a Prospective Cohort Study of 77 Hospitalized Men

49 citations , January 2021 in “Journal of The European Academy of Dermatology and Venereology”

Anti-androgens, like finasteride, dutasteride, and spironolactone, may lessen the severity of COVID-19 in men, leading to fewer ICU admissions.

Racial Variations in COVID-19 Deaths May Be Due to Androgen Receptor Genetic Variants Associated with Prostate Cancer and Androgenetic Alopecia. Are Anti-Androgens a Potential Treatment for COVID-19?

research Racial Variations in COVID-19 Deaths May Be Due to Androgen Receptor Genetic Variants Associated with Prostate Cancer and Androgenetic Alopecia. Are Anti-Androgens a Potential Treatment for COVID-19?

71 citations , April 2020 in “Journal of Cosmetic Dermatology”

This article discusses the potential link between genetic variants associated with androgen receptor activity and racial variations in COVID-19 mortality, suggesting a possible role for anti-androgens in treatment, but reports no new clinical findings.

A Preliminary Observation: Male Pattern Hair Loss Among Hospitalized COVID-19 Patients in Spain – A Potential Clue to the Role of Androgens in COVID-19 Severity

research A Preliminary Observation: Male Pattern Hair Loss Among Hospitalized COVID-19 Patients in Spain – A Potential Clue to the Role of Androgens in COVID-19 Severity

134 citations , April 2020 in “Journal of Cosmetic Dermatology”

Male pattern hair loss could hint at androgens affecting COVID-19 severity.

research What Does Androgenetic Alopecia Have to Do with COVID-19? An Insight into a Potential New Therapy

47 citations , April 2020 in “Dermatologic Therapy”

This letter discusses the potential connection between androgenetic alopecia and COVID-19, suggesting a possible new therapy, but it reports no new results.

research Safety of 5α-Reductase Inhibitors and Spironolactone in Breast Cancer Patients Receiving Endocrine Therapies

22 citations , November 2018 in “Breast Cancer Research and Treatment”

In this review, researchers found no evidence of interactions between 5α-reductase inhibitors or spironolactone and endocrine therapies for breast cancer, with no consistent changes in estrogen levels or increased breast cancer risk associated with spironolactone usage.

research Safety Concerns When Using Novel Medications to Treat Alopecia

23 citations , October 2018 in “Expert Opinion on Drug Safety”

This review discusses the safety concerns associated with new treatments for non-scarring alopecias, highlighting that while these therapies such as JAK inhibitors and oral minoxidil show efficacy in hair regrowth, their safety profiles vary significantly, requiring careful consideration of benefits and risks.

research Studying the Correlation of Renin-Angiotensin-System Components and Insulin Resistance in Polycystic Ovary Syndrome

12 citations , March 2013 in “Gynecological Endocrinology”

This study found that women with PCOS had significantly higher angiotensin converting enzyme activity and insulin resistance compared to controls, suggesting a correlation between these factors.

research The Rationale for Inhibiting 5α-Reductase Isoenzymes in the Prevention and Treatment of Prostate Cancer

108 citations , February 2008 in “The Journal of urology/The journal of urology”

This review discusses the rationale for targeting 5α-reductase isoenzymes in prostate cancer prevention and treatment, highlighting the potential benefits of using inhibitors like dutasteride and finasteride but reports no new experimental results.